Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas

Бабкина, И. В.; Osipov, D. A.; Solovyov, Yu. N.; Булычева, И. В.; Мачак, Г.; Aliev, M. D.; Kushlinsky, N. Е.

doi:10.1007/s10517-009-0710-0

Cited by 12 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our series, the largest so far conducted in this setting, VEGF levels had no significant impact on outcome, in agreement with Rutkowski et al [25]. As in previous studies of bFGF [13, 25], we found no clinical value of this angiogenic factor in osteosarcoma. Here, as in the study by Rastogi et al [23], serum VEGF levels fell significantly between baseline and surgery, with a slightly larger variation in patients who had a good histologic response.…”

Section: Discussionsupporting

confidence: 93%

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

et al. 2017

View full text Add to dashboard Cite

BackgroundAngiogenesis is essential for the progression and metastatic spread of solid tumours. Expression of vascular endothelial growth factor (VEGF) has been linked to poor survival among osteosarcoma patients but the clinical relevance of monitoring blood and urine angiogenic factors is uncertain. The aim of this study was to determine the prognostic significance of blood VEGF and blood and urinary basic fibroblast growth factor (bFGF) levels in osteosarcoma patients, both at diagnosis and during treatment.MethodsPatients with localised or metastatic osteosarcoma enrolled in OS2005 and OS2006 studies between 2005 and 2011 were prospectively included in this study. VEGF and bFGF levels in serum and plasma and bFGF levels in urine were measured by ELISA at diagnosis, before surgery, and at the end of treatment. Endpoints considered for the prognostic analysis were histological response, progression-free and overall survival. Kruskal-Wallis tests were used to compare the distribution of baseline biomarker values across the different subgroups, and paired sample Wilcoxon rank tests were used to analyze changes over time. Association between biomarker levels and outcomes were assessed in multivariable models (logistic regression for histologic response, and Cox models for survival).ResultsSamples were available at diagnosis for 269 patients (54% males; age ≤ 18 years: 73%; localised disease in 68%, doubtful lung lesions in 17%, and metastases in 15%). High serum VEGF and bFGF levels were observed in respectively 61% and 51% of patients. Serum and plasma VEGF values were not strongly correlated with one another (r = 0.53). High serum and plasma VEGF levels were significantly more frequent in patients with large tumours (≥10 cm; p = 0.003 and p = 0.02, respectively). VEGF levels fell significantly during pre-operative chemotherapy (p < 0.0001). No significant correlation was found between this variation and either the histological response, progression-free survival or overall survival (p = 0.26, p = 0.67, and p = 0.87, respectively). No significant association was found between blood or urinary bFGF levels and clinical characteristics, histological response, or survival.ConclusionsLevels of VEGF and bFGF angiogenic factors are high in most osteosarcoma patients, but have no significant impact on response to chemotherapy or outcome in this large prospective series.OS 2006 trial registration number clinicaltrials.gov NCT00470223; date of registration: May 3th 2007.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3409-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 93%

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Placenta growth factor (PIGF) is a dimeric glycoprotein with structural and functional similarities to VEGF [75]. PIGF serves a function in tumor angiogenesis [76][77][78]. Previous studies indicated that overexpression of PIGF had a close relation with early recurrence of HCC [79,80], and our finding showed PIGF had higher serum levels in HCC, suggested that PIGF may be a prognostic indicator and a diagnostic biomarker of HCC.…”

Section: Discussionsupporting

confidence: 61%

Serum Cytokine Analysis in Patients with Hepatocellular Carcinoma

Qiao¹,

Zhang²,

Gu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is one of most common cancers with a high mortality rate. HBV/HCV infection is an important risk factor to trigger HCC. Therefore, developing serum biomarkers for early diagnosis is crucial to prolong survival in HCC patients. Methods: An antibody array technology was utilized to detect serum from 20 HBV-related HCC patients, 20 chronic hepatitis B patients and 20 normal population, whose results were further validated by ELISA. Results: Both antibody array and ELISA showed that ten growth factors (SCF R, GDF-15, HGF, FGF-4, IGFBP-1, PIGF, GH, GDNF, BDNF and IGF-1) were significantly differential in HCC patients when compared to the non-HCC population. Among these growth factors, the levels of SCF R, GDF-15, HGF, GH and IGF-1 showed significant correlation with hepatitis B and its severity, indicating that these growth factors may promote HCC progression by an HBV-specific mechanism. A therapy targeting these growth factors in hepatitis B patients may help to prevent the development of HCC. FGF4 and GH were found, for the first time, to be upregulated in HCC, suggesting that these two growth factors may serve as novel serum biomarkers for the early diagnosis of HCC. Conclusion: The combined detection of all the differential growth factors may improve the diagnostic accuracy of HCC.

show abstract

“…Mice overexpressing FGF23 display increased expression of Runx2 and alkaline phosphatase, receptor activator of NFκB ligand or RANKL and osteoprotegerin transcripts, MMP9 and cathepsin K immunoexpression along with increased serum concentrations of C terminal telopeptide of collagen (CTX) with increased bone resorptive activity [61]. Vitamin D mediated down regulation of FGF1 in OS cells is significant as previous studies have detected increased levels of serum FGF1 and FGFR1 amplification in OS patients [62,63]. FGF1 mediated activation of PKA and PKC signaling pathways induces nucleoside triphosphate pyrophosphohydrolase (NTPPPH) expression in OS cells [64].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells

Garimella

Tadikonda

Tawfik

et al. 2017

IJMS

View full text Add to dashboard Cite

Osteosarcoma (OS) is an aggressive malignancy of bone affecting children, adolescents and young adults. Understanding vitamin D metabolism and vitamin D regulated genes in OS is an important aspect of vitamin D/cancer paradigm, and in evaluating vitamin D as adjuvant therapy for human OS. Vitamin D treatment of 143B OS cells induced significant and novel changes in the expression of genes that regulate: (a) inflammation and immunity; (b) formation of reactive oxygen species, metabolism of cyclic nucleotides, sterols, vitamins and mineral (calcium), quantity of gap junctions and skeletogenesis; (c) bone mineral density; and (d) cell viability of skeletal cells, aggregation of bone cancer cells and exocytosis of secretory vesicles. Ingenuity pathway analysis revealed significant reduction in Runx2 target genes such as fibroblast growth factor -1, -12 (FGF1 and FGF12), bone morphogenetic factor-1 (BMP1), SWI/SNF related, matrix associated actin dependent regulator of chromatin subfamily a, member 4 (SMARCA4), Matrix extracellular phosphoglycoprotein (MEPE), Integrin, β4 (ITGBP4), Matrix Metalloproteinase -1, -28 (MMP1 and MMP28), and signal transducer and activator of transcription-4 (STAT4) in vitamin D treated 143B OS cells. These genes interact with the inflammation, oxidative stress and membrane vesicle biogenesis gene networks. Vitamin D not only inhibited the expression of Runx2 target genes MMP1, MMP28 and kallikrein related peptidase-7 (KLK7), but also migration and invasion of 143B OS cells. Vitamin D regulated Runx2 target genes or their products represent potential therapeutic targets and laboratory biomarkers for applications in translational oncology.

show abstract

Endostatin, Placental Growth Factor, and Fibroblast Growth Factors-1 and -2 in the Sera of Patients with Primary Osteosarcomas

Cited by 12 publications

References 13 publications

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study

Serum Cytokine Analysis in Patients with Hepatocellular Carcinoma

Vitamin D Impacts the Expression of Runx2 Target Genes and Modulates Inflammation, Oxidative Stress and Membrane Vesicle Biogenesis Gene Networks in 143B Osteosarcoma Cells

Contact Info

Product

Resources

About